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Introduction
Patients with malignant glioma have a very poor prognosis, with an average survival time of less than 2 years even with extensive treatment including surgical resection, radiation, and a variety of immunochemotherapies.
1,2 Molecular neurosurgery using gene therapy has been investigated clinically since 1992 in efforts to overcome this formidable neoplasm. These clinical trials consisted of two approaches: suicide gene therapy using the herpes simplex virus-thymidine kinase (HSV-tk) gene with administration of ganciclovir (GCV) and immune gene therapy using cytokine genes. With respect to the former, Ram et al 3 reported in 1997 that therapeutic efficacy was limited to patients with small malignant brain tumors. They suggested that further development of techniques for delivery and distribution of therapeutic genes would be necessary to achieve effectiveness with the suicide gene approach.
In the 1980s it was demonstrated that intravenous or intrathecal administration of interferon-␤ (IFN-␤) has a definite growth-inhibitory effect on malignant glioma and IFN-␤ therapy has proven useful as postoperative adjuvant treatment of these tumors. [4] [5] [6] [7] Apart from exogenous IFN, autocrine interferon secretion has been found to regulate growth of glioma
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Received 16 April 1998; accepted 4 May 1999 cells. 8 Larsson et al 9 demonstrated that a high dose of IFN-␤ could be produced by glial and glioma cell lines by superinduction, and that the IFN-␤ produced had a cytostatic and/or cytocidal effect. IFN nullizygosity localized to chromosome 9p has been demonstrated in many malignant glioma specimens. 10 These findings suggested the possibility of a still stronger antitumor effect if glioma cells were transfected with the IFN-␤ gene.
Therefore, since 1988 we have been developing cytokine gene therapy using novel cationic liposomes as an in vivo gene transfer system for the IFN-␤ gene. Our previous in vitro experiments have demonstrated that cationic liposome-mediated human IFN-␤ (HuIFN-␤) gene transfer to cultured human glioma cells resulted in production of HuIFN-␤ and showed much stronger growthinhibitory effect on the cells than exogenous HuIFN-␤. 11, 12 In in vivo experiments using nude mice, HuIFN-␤ was secreted by subcutaneously or intracranially implanted human glioma after transfer of its gene by means of cationic liposomes, and as a result tumor growth was markedly inhibited. [13] [14] [15] Furthermore, we pointed out in an experimental glioma established in nude mouse brain that activation of natural killer cells was very important for efficacy of the IFN-␤ gene therapy. 16 In the present study we evaluated antitumor effect and activation of T cell-mediated cellular immunity resulting from injection of liposomes containing the murine IFN-␤ (muIFN-␤) gene into a syngeneic intracranial mouse glioma.
Results

In vitro experiments
Transfer of muIFN-␤ gene to mouse glioma GL261 cells by cationic liposomes and muIFN-␤ production: Aliquots of 2 × 10 4 GL261 cells were inoculated with 1.5 ml of medium and incubated at 37°C for 24h, liposomes containing pSV2muIFN-␤ [lip(pSV2muIFN-␤)] (10 nmol of lipid/0.2 g of DNA/ml or 20 nmol of lipid/0.4 g of DNA/ml) were added to the medium, and incubation was continued for up to 8 days. The culture medium was collected on days 2, 4, 6 and 8 after addition of liposomes, and muIFN-␤ concentration in the medium was measured by a bioassay.
Production of muIFN-␤ was found in the conditioned medium of GL261 cells transfected with lip(pSV2muIFN-␤), but was not found when phosphate buffered saline (PBS), empty liposomes, or naked pSV2muIFN-␤ were added to cells. The level of muIFN-␤ increased up to day 6 after addition of lip(pSV2muIFN-␤), reaching 73.5 ± 19.6 IU/ml at maximum, and decreased on day 8 (Table 1) .
Growth inhibition of GL261 cells treated with Lip(pSV2muIFN-␤):
As shown in Figure  1 , lip(pSV2muIFN-␤) suppressed growth of GL261 cells significantly. Twenty nanomoles of lipid per milliliter of lip(pSV2muIFN-␤) had a slightly stronger growth-inhibitory effect than 10 nmol of lipid/ml. In contrast, empty liposomes (20 nmol of lipid/ml), 100 IU/ml of muIFN-␤, or pSV2muIFN-␤ (0.4 g of DNA/ml) did not reduce cell growth significantly. Although 1000 IU/ml of muIFN-␤ and 20 nmol of lipid/ml of liposome containing pCH110 [lip(pCH110)] suppressed cell growth significantly, its growth-inhibitory effect was significantly less than that of 20 nmol of lipid/ml of lip(pSV2muIFN-␤) (P Ͻ 0.01).
In vivo experiments
Establishment of intracerebral glioma model in mice: First, to confirm that the injected GL261 glioma cells had formed tumors in brains of C57BL/6 mice on day 4 after injection, three mice were killed at that time-point and coronal brain sections were examined after hematoxylin and eosin (H and E) staining. Gliomas were established 
cells were plated and incubated with phosphate buffered saline (PBS), empty liposomes (empty), murine IFN-␤ (muIFN-␤), pSV2muIFN-␤, liposome containing pCH110 [lip(pCH110)], or liposome containing pSV2muIFN-␤ [lip(pSV2muIFN-␤)] 24 h after inoculation.
Mean tumor volume in group 6 was 3.4 ± 1.6 mm 3 , compared with 54.0 ± 19.8 mm 3 in group 1, 48.0 ± 20.8 in group 2, 66.6 ± 15.0 in group 3, 67.0 ± 14.4 in group 4, and 43.6 ± 7.9 in group 5. The difference between groups 1 and 6 was 16-fold and statistically significant, while differences between group 1 and groups other than 6 showed no statistical significance ( Figure 5 ).
To examine the survival time of treated animals, mice were separated into six groups on day 7 after tumor cell injection: 1, treated with PBS (2 l); 2, treated with empty liposomes (40 nmol of lipid in 2 l of PBS); 3, treated with murine IFN-␤ (1000 IU in 2 l of PBS); 4, treated with pSV2muIFN-␤ (0.8 g of DNA in 2 l of PBS); 5, treated with liposome containing pCH110 (40 nmol of lipid and 0.8 g of DNA in 2 l of PBS); and 6, treated with liposome containing pSV2muIFN-␤ (40 nmol of lipid and 0.8 g of DNA in 2 l of PBS). Median survival time of those groups were 32.6, 42.6, 32.0, 32.4, 36.2 and 41.8 days, respectively. Although the difference in host survival time between group 1(PBS) and group 6 [lip(pSV2muIFN-␤)] was not statistically significant (median survival times, 32.6 and 41.8 days, respectively), we noted two surviving mice with no neurologic symptoms at day 100 among the five mice in group C ( Figure  6 ). These surviving animals were challenged with injection of 2 × 10 6 GL261 cells into their right legs on day 100. No tumors developed in these animals over a 50-day period, while two control mice injected with GL261 cells developed tumors.
Activation of host cellular immune response by Lip(pSV2muIFN-␤):
To evaluate whether lip(pSV2muIFN-␤) injection into intracerebral gliomas activated cellular immunity, we immunocytochemically studied the presence and localization of infiltrating T lymphocytes (T cells) within the brain. Two mice in each of the six groups described above were killed on days 11 and 23 after tumor transplantation (days 7 and 19 after treatment) for immunocytochemical studies.
In group 6 [lip(pSV2muIFN-␤)], CD3 + cells were detectable by day 11 after transplantation ( Figure 7a ). These cells had infiltrated selectively into the tumor, with only a small number of cells present in surrounding tissues. These T cells were mainly CD8 + (Figure 7c ), but CD4
+ cells also could be detected (Figure 7b ). T cell infiltration into the tumor persisted for more than 10 days and tended to increase until day 23 (data not shown).
In group 4 (pSV2muIFN-␤), neither CD4 + nor CD8 + cells were detectable on day 11 (Figure 7e , f). However, CD3 + cells were observed within the tumor until day 23 in smaller numbers than in group 6. In group 1 (PBS), group 2 (empty liposomes), and group 3 (muIFN-␤), the amount of T-cell infiltration was similar to that seen in group 4 (pSV2muIFN-␤) at corresponding time-points (data not shown). In group 5 [lip(pCH110)], relatively large numbers of CD3 + and CD8 + cells had infiltrated in the tumor on day 11 (Figure 7g , i) and day 23, although fewer of these cells had infiltrated than in group 6.
Discussion
Our group is now planning to apply cytokine gene therapy to treatments of patients with malignant glioma. Our strategy, which involves repeated intratumoral injections of cationic liposomes containing the human IFN-␤ (HuIFN-␤) gene into the residual tumor after surgery, is based on several observations from our previous studies. Intravenous or intrathecal administration of HuIFN-␤ has shown clinical effectiveness against malignant glioma.
4-6
As chemotherapeutic agents, nitrosoureas such as ACNU and MCNU are considered most effective against malignant glioma. 17, 18 HuIFN-␤ can behave as a drug or radiation sensitizer, enhancing toxicity against gliomas and a variety of neoplasms when given in combination with chemotherapeutic agents such as nitrosoureas. 6 Cationic liposome-mediated HuIFN-␤ gene transfer results in a much stronger inhibition of glioma cell growth than does exogenous HuIFN-␤. 11, 12 A 40-fold increase in concentration of HuIFN-␤ is needed to obtain an inhibitory effect similar to that seen with HuIFN-␤ gene transfer. HuIFN-␤ gene transfer induced a cytocidal, not cytostatic, response in human glioma cells, probably involving apoptosis. 19 Growth of subcutaneous or intracerebral human gliomas in nude mice was markedly inhibited after treatment with cationic liposomes containing the HuIFN-␤ gene. 13, 14 In addition, we demonstrated that the induction of NK cells is important in the cytocidal effect of liposomes containing the HuIFN-␤ gene on experimental gliomas. 16 Thus, HuIFN-␤ gene transfer is thought to possess multiple factors conveying antitumor activity. In addition, IFN-␤ has been reported to support the differentiation of cytotoxic T lymphocytes (CTL) and to augment the antitumor immune response by inducing tumor-specific CTL. 20 Our previous experimental studies of gene therapy prompted us to examine antitumor immunity in immunocompetent animals, so we treated syngeneic intracerebral gliomas with the murine IFN-␤ gene.
Before in vivo studies, we demonstrated that cationic liposome-mediated muIFN-␤ gene transfer had a much stronger growth-inhibitory effect on mouse glioma cells than exogenous muIFN-␤, even when the amount added to cultures was 13-fold ( Figure 1) . Production of muIFN-␤ by GL261 mouse glioma cells transfected with pSV2mu-IFN-␤ was seen to persist for more than 8 days after a single transfection (Table 1) . These results were similar to observations in human cell lines. 11, 12 In in vivo studies, a single injection of lip(pSV2muIFN-␤) resulted in a significant antitumor effect on mouse intracerebral glioma in immunocompetent C57BL/6 mice (Figures 4 and 5) . As shown in Figure 2 , liposomemediated gene transduction efficiency is not high (less than 10%). As shown in Figure 3 , approximately 10% of a lysate from tumor tissue yielded a dense band qualitatively and quantitatively similar to a standard blot known to represent 100 IU of muIFN-␤, suggesting that the amount of this cytokine produced was approximately 1000 IU. Thus, remarkable antitumor effect despite a low transduction efficiency led us to suspect other, less indirect IFN-␤-mediated actions including activation of cellular immunity. In the present study we demonstrated larger numbers of CD3 + , CD4 + , and CD8 + T cells within the tumors in treated mice than in those of any other controls including mice treated with lip(pCH110). Although several recent reports have indicated that expression of the LacZ gene enhances antitumor immunity, 21 this effect did not overcome that of lip(pSV2muIFN-␤) in this study. In general, MHC class I-restricted CD8 + T cells are considered important to the antitumor immune response. Primary brain tumors including gliomas are not highly immunogenic, but von Hoegen et al 20 have demonstrated that type I-IFN, especially IFN-␤, induces an immune response even against poorly immunogenic tumors. We administered recombinant muIFN-␤ intratumorally on day 4 after tumor transplantation, but it failed to induce an immune response. Kuroki et al 22 have demonstrated that intraperitoneal administration of recombinant muIFN-␤ in subcutaneous malignant glioma models enhanced natural killer cell and CTL populations, but these immunologic effects of muIFN-␤ had declined by day 7. 22 In contrast, we presently demonstrated CTL not only on day 7 but also on day 19 after a single injection for muIFN-␤ gene transfer. This observation indicates a more persistent activation of the immune response by muIFN-␤ gene transfer than by exogenous muIFN-␤ protein.
The present results suggest that liposome/IFN-␤ genebased gene therapy should be effective for treating patients with malignant glioma. In further studies, it will be necessary to determine whether the treatment-associated CTL we demonstrated has specific antitumor effects.
Materials and methods
Cell line
The murine glioma cell line, GL261, was cultured in Eagle's minimum essential medium supplemented with 10% fetal calf serum, 2 mm nonessential amino acids, 5 mm lglutamine, streptomycin (100 g/ml) and penicillin (100 units/ml).
Plasmids
Plasmids designated pSV2muIFN-␤ and pCH110 were used. The former plasmid contains the SV40 early promoter and the muIFN-␤ coding sequence. The pCH110 is a plasmid expressing ␤-galactosidase driven by SV40 early promoter (Pharmacia, Uppsala, Sweden).
Preparation of liposomes containing plasmids
Cationic liposomes were prepared from N-(␣-trimethylammonioacetyl)-didodecyl-d-glutamate chloride (TMAG), dilauroyl phosphatidylcholine (DLPC), and dioleoyl phosphatidylethanolamine (DOPE) as described in our previous paper. 13, 14, 19 The liposomes prepared were multilamellar vesicles. We prepared two kinds of liposomes containing a plasmid: a liposome containing pSV2muIFN-␤ [lip(pSV2muIFN-␤)] and a liposome containing pCH110 [lip(pCH110)].
Gene transfer into cultured cells
Aliquots of 2 × 10 4 GL261 cells were inoculated in each well of a Falcon plate (No. 3046) with 1.5 ml of medium and incubated at 37°C for 24 h in a humidified atmos- phere of 5% CO 2 and 95% air. Lip(pSV2muIFN-␤) (10 nmol of lipid/0.2 g of DNA/ml or 20 nmol of lipid/0.4 g of DNA/ml) were added to the medium, and incubation was continued for up to 8 days. The culture medium was collected on days 2, 4, 6 and 8 after addition of liposomes, and muIFN-␤ concentration in the medium was measured.
Concentration of muIFN-␤ in medium
The muIFN-␤ activity of culture supernatants was assayed by the decrease in cytopathic effect of vesicular stomatitis virus on mouse L cells. Activity was expressed in cytopathic units (CPU), calibrated against reference international mouse interferon, as previously described. 23 The assay was performed as a gift by Toray Industries, Tokyo, Japan.
Growth inhibition
Growth inhibition of GL261 cells transfected with lip(pSV2muIFN-␤) was evaluated using a hemocytometer, counting numbers of viable cells excluding trypan blue. As controls, PBS (15 l), empty liposomes (20 nmol of lipid/ml), recombinant muIFN-␤ (100 and 1000 IU/ml), pSV2muIFN-␤ (0.4 g of DNA/ml), and lip(pCH110) (20 nmol of lipid/0.4 g of DNA/ml) were used.
Animals
Male C57BL/6 mice (10 to 12 weeks old) were used. They were kept under pathogen-free conditions in the animal facility of our institute. Animal experiments were performed according to the principles enunciated in the Guide for the Care and Use of Laboratory Animals prepared by the Office of the Prime Minister of Japan.
Brain tumor model
Mice were anesthetized with an intraperitoneal injection of pentobarbital (60 to 70 mg/kg of body weight). After hair shaving and scalp incision, a burr hole was made in the skull 3 mm lateral to the midline and 4 mm posterior to the bregma using a dental drill. The head of each mouse was fixed in a stereotactic apparatus with ear bars. Then 2 × 10 5 GL261 cells in 2 l of PBS were injected stereotactically over 4 min at a depth of 2 mm below the dura mater. A sterile Hamilton syringe fitted with a 26-gauge needle was used with a microsyringe pump. The needle was left in the brain for 2 additional min and then was slowly withdrawn.
Figure 7 Immunocytochemistry for T lymphocytes infiltrating within the brain tumor on day 7 after intratumoral injection of liposome containing pSV2muIFN-␤ [lip(pSV2muIFN-␤)] (a-c), pSV2muIFN-␤ (naked DNA) (d-f) and liposome containing pCH110 [lip(pCH110)] (g-i). (a) Large numbers of CD3
To determine whether the injected cells produced a tumor, three mice were killed on day 4 after tumor cell injection. The brains were removed and fixed in 10% formalin in 0.1 m phosphate buffer. Coronal sections were taken from the injection site and stained with H and E.
Histological detection of ␤-galactosidase For detection of LacZ gene expression, we injected mice intracranially with lip(pCH110) (40 nmol of lipid and 0.8 g of DNA in 2 l of PBS) on day 4 after tumor cell injection. Two days later the mice were killed and their brains were frozen in OCT compound. Frozen sections (30 m) were fixed in 2.5% glutaraldehyde in PBS, and stained with X-gal before counterstaining with H and E.
Detection of murine IFN-␤ Mice were injected intracranially with lip(pSV2muIFN-␤) (40 nmol of lipid and 0.8 g of DNA in 2 l of PBS) on day 4 after tumor cell injection. We used PBS, empty liposomes (40 nmol of lipid in 2 l of PBS), and pSV2muIFN-␤ (0.8 g of DNA in 2 l of PBS) as controls. After the mice were killed 2 days later, the brain tumors were removed and homogenized in 0.1 m phosphate buffer. Supernatants were collected after removing debris by centrifugation, and these were heated at 99°C for 3 min with Laemmli sample buffer. Total protein (20 g) was subjected to 15% sodium dodecyl sulfate polyacrylamide gel elecrophoresis (SDS-PAGE) and transferred on to a polyvinylide difluoride membrane and blotted. We used sheep anti-mouse IFN-␣/␤ polyclonal antibody (PBL Biomedical Laboratories, Newbrunswick, NJ, USA) (1:1000 dilution) preabsorbed overnight at 4°C by 100 g of normal brain lysate in 1% bovine serum albumin (BSA)/5% skim milk/PBS as a primary antibody and horseradish peroxidase-conjugated rabbit antibody to sheep IgG (ICN Pharmaceuticals, OH, USA) in 5% skim milk/PBS at a 1:5000 dilution as a second antibody. The bands were visualized by ECL. The membrane was stained with Coomassie blue to confirm that an equal amount of protein had been loaded in each lane.
Treatments
Animals were divided into six groups: group 1, treated with PBS; 2, treated with empty liposomes; 3, treated with muIFN-␤ (1000 IU); 4, treated with pSV2muIFN-␤ (naked DNA); 5, treated with lip(pCH110); and 6, treated with lip(pSV2muIFN-␤).
On day 4 after tumor cell injection, PBS (2 l), empty liposomes (40 nmol of lipid in 2 l of PBS), muIFN-␤ (1000 IU in 2 l of PBS), pSV2muIFN-␤ (0.8 g of DNA in 2 l of PBS), lip(pCH110) (40 nmol of lipid and 0.8 g of DNA in 2 l of PBS), and lip(pSV2muIFN-␤) (40 nmol of lipid and 0.8 g of DNA in 2 l of PBS) were injected intracranially at the tumor site in each group. Two mice in each group were killed on days 11 and 23 after tumor cell injection, thier brains were removed and frozen in OCT compound for immunocytochemistry. All remaining mice were killed on day 23 after tumor cell injection, and their brains were fixed in 10% formalin in 0.1 m phosphate buffer for subsequent H and E staining of coronal sections. Immunocytochemistry First, 10-m frozen sections through the injection site were cut with a cryostat microtome and mounted on silanized glass slides. Sections were fixed for 15 min in acetone at 4°C, and after washing in PBS they were blocked with 1% skim milk in PBS. The following monoclonal antibodies were used to detect immune system markers: KT3 (rat anti-mouse CD3; Serotec, Oxford, UK), KT174 (rat anti-mouse CD4; Serotec), and YTS 105.18 (rat antimouse CD8; Serotec). The secondary antibody was biotinylated rabbit anti-rat IgG (H and L chains) absorbed with mouse serum (Vector Laboratories, Burlingame, CA, USA). The sections were incubated with primary antibodies for 1 h at room temperature, and then were immersed in 0.3% H 2 O 2 in absolute methanol for 15 min to block endogenous peroxidase. After being washed three times in PBS, sections were incubated with biotinylated rabbit anti-rat IgG (H and L) for 30 min at room temperature. Diaminobenzidine solution was used as a chromogen, and the sections were counterstained with hematoxylin.
Tumor growth inhibition and survival time
